Allelic loss of HLA class I facilitates evasion from immune surveillance in cervical intraepithelial neoplasia
- PMID: 38837741
- DOI: 10.1111/tan.15509
Allelic loss of HLA class I facilitates evasion from immune surveillance in cervical intraepithelial neoplasia
Abstract
Loss of heterozygosity (LOH) has been reported to occur in HLA regions in cervical intraepithelial neoplasia (CIN) and cervical cancer. However, the details of how this is related to the progression of CIN have been unclear. In this study, we examined the human papillomavirus (HPV) antigen-presenting capacity of people with CIN and the significance of LOH of HLA class I in the progression of CIN. It was shown that differences in antigen-presenting capacity among each case depended on HLA types, not HPV genotypes. Focusing on the HLA type, there was a positive correlation between antigen-presenting capacity against HPV and the frequency of allelic loss. Furthermore, the lost HLA-B alleles had a higher HPV antigen-presenting capacity than intact alleles. In addition, frequency of LOH of HLA class I was significantly higher in advanced CIN (CIN2-3) than in cervicitis or early-stage CIN (CIN1): around half of CIN2-3 had LOH of any HLA class I. Moreover, the antigen-presenting capacity against E5, which is the HPV proteins that facilitate viral escape from this immune surveillance by suppressing HLA class I expression, had the most significant impact on the LOH in HLA-B. This study suggests that HPV evades immune surveillance mechanisms when host cells lose the capacity for antigen presentation by HLA class I molecules, resulting in long-term infection and progression to advanced lesions.
Keywords: HLA class I; cervical cancer; cervical intraepithelial neoplasm; human papillomavirus; loss of heterozygosity.
© 2024 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
References
REFERENCES
-
- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7‐30. doi:10.3322/caac.21332
-
- Tsikouras P, Zervoudis S, Manav B, et al. Cervical cancer: screening, diagnosis and staging. J BUON. 2016;21(2):320‐325.
-
- Zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer. 2002;2(5):342‐350. doi:10.1038/nrc798
-
- Ronco G, Giorgi‐Rossi P, Carozzi F, et al. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet Oncol. 2010;11(3):249‐257. doi:10.1016/S1470‐2045(09)70360‐2
-
- Castle PE, Stoler MH, Wright TC, Sharma A, Wright TL, Behrens CM. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study. Lancet Oncol. 2011;12(9):880‐890. doi:10.1016/S1470‐2045(11)70188‐7
Publication types
MeSH terms
Substances
Grants and funding
- 21H02772/The Japan Society for the Promotion of Science (JSPS)
- 22K09566/The Japan Society for the Promotion of Science (JSPS)
- 21K15072/The Japan Society for the Promotion of Science (JSPS)
- JP21cm0106502/Japan Agency for Medical Research and Development
- JP22ck0106723/Japan Agency for Medical Research and Development
- JP22ck0106724/Japan Agency for Medical Research and Development
- JP23ama221528/Japan Agency for Medical Research and Development
- JP16ck0106178/Japan Agency for Medical Research and Development
- JP22wm0325014/Japan Agency for Medical Research and Development
- JP23wm0325057/Japan Agency for Medical Research and Development
- Chiba Prefecture Budget
- The Seiichi Imai Memorial Foundation
- Taiju Life Social Welfare Foundation
- Takeda Science Foundation
- Princess Takamatsu Cancer Research Fund
- Uehara Memorial Foundation
- NOVARTIS Foundation (Japan) for the Promotion of Science
- Kobayashi Foundation for Cancer Research
- The Kashiwado Memorial Foundation
LinkOut - more resources
Full Text Sources
Medical
Research Materials